These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18855625)

  • 21. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CoMSIA study on substituted aryl alkanoic acid analogs as GPR40 agonists.
    Bhatt A; Patel PD; Patel MR; Singh S; Lau-Cam CA; Talele TT
    Chem Biol Drug Des; 2011 May; 77(5):361-72. PubMed ID: 21352503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the CNS to treat type 2 diabetes.
    Sandoval DA; Obici S; Seeley RJ
    Nat Rev Drug Discov; 2009 May; 8(5):386-98. PubMed ID: 19404312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Free fatty acid receptors and their physiological role in metabolic regulation].
    Hirasawa A; Hara T; Ichimura A; Tsujimoto G
    Yakugaku Zasshi; 2011; 131(12):1683-9. PubMed ID: 22129861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiology and therapeutics of the free fatty acid receptor GPR40.
    Huang H; Dai MH; Tao YX
    Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus.
    Mo XL; Wei HK; Peng J; Tao YX
    Prog Mol Biol Transl Sci; 2013; 114():251-76. PubMed ID: 23317787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.
    Hoque M; Ali S; Hoda M
    Int J Biol Macromol; 2018 Oct; 118(Pt B):2237-2244. PubMed ID: 30030074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats.
    Zhang X; Yan G; Li Y; Zhu W; Wang H
    Biomed Pharmacother; 2010 Nov; 64(9):647-51. PubMed ID: 20888730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continued discovery of ligands for G protein-coupled receptors.
    Lee DK; George SR; O'Dowd BF
    Life Sci; 2003 Dec; 74(2-3):293-7. PubMed ID: 14607257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia.
    Chen JJ; Gong YH; He L
    J Drug Target; 2019 Apr; 27(4):347-354. PubMed ID: 29929407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors.
    Ahmed K; Tunaru S; Offermanns S
    Trends Pharmacol Sci; 2009 Nov; 30(11):557-62. PubMed ID: 19837462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A family of fatty acid binding receptors.
    Brown AJ; Jupe S; Briscoe CP
    DNA Cell Biol; 2005 Jan; 24(1):54-61. PubMed ID: 15684720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer.
    Perumalsamy S; Aqilah Mohd Zin NA; Widodo RT; Wan Ahmad WA; Vethakkan SRDB; Huri HZ
    Curr Pharm Des; 2017; 23(25):3689-3698. PubMed ID: 28625137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.